Comparing reboot surgery and conventional full-house FESS for adults with recurrent nasal polyps (CRSwNP)
Official title: "Comparative Outcomes of Mucosal Reset (Reboot) Versus Complete Sinusotomy (Full House FESS) in CRSwNP: A Prospective Study
Run by Kafrelsheikh University · NCT07368361 · Data updated 2026-11-12
This trial will test whether reboot surgery or conventional full-house FESS better prevents polyp return and improves symptoms for adults with refractory CRSwNP.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Kafrelsheikh University Academic / other |
| Locations | 1 site (Egypt, Kafrelsheikh) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | June 1, 2026 |
| Study ends | September 1, 2026 |
| Registry record updated | May 28, 2026 |
| Trial ID | NCT07368361 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with refractory CRSwNP who have failed at least one prior FESS or biologic, have evidence of type-2 inflammation (blood/tissue eosinophilia or IgE ≥100 IU/mL), and a Lund–Mackay CT score ≥10 are ideal candidates.
✕Probably not a fit
Patients with non–type-2 disease, unilateral nasal inflammatory conditions, recent treatment with monoclonal antibodies (within 12 months), eosinophilic granulomatosis with polyangiitis (EGPA), severe uncontrolled systemic disease, or who are unfit for general anesthesia are unlikely to benefit from or be eligible for this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized controlled trial will enroll adults with refractory CRSwNP and randomly assign them to either reboot surgery (complete removal of inflamed mucosa to the periosteum) or conventional full-house endoscopic sinus surgery (FESS). The primary outcome is polyp recurrence at 24 months, defined by an endoscopic polyp score of ≥2. Secondary outcomes include recurrence-free survival, changes in SNOT-22 quality-of-life scores, systemic corticosteroid use, complication rates, and cost-effectiveness. All surgeries and follow-up visits are conducted at Kafrelsheikh Faculty of Medicine with standardized surgical and follow-up protocols.
Why it matters
Potential benefit: If successful, reboot surgery could reduce polyp recurrence, extend symptom-free periods, lower steroid requirements, and improve quality of life compared with conventional FESS.
How similar studies have gone: Smaller case series and retrospective reports have suggested reboot surgery can lower recurrence rates compared with standard ESS, but high-quality randomized data are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:Patients above the age of 18 years presenting with recurrent refractory CRSwNP (failed ≥1 biologic/prior FESS), Type-2 endotype confirmation (blood/tissue eosinophilia, IgE ≥100 IU/mL), Lund-Mackay CT score ≥10 will be included in the study. Exclusion Criteria: eosinophilic granulomatosis with polyangiitis (EGPA) or severe systemic diseases (except controlled asthma or NSAID-exacerbated respiratory disease), neoplasms, vasoconstrictor abuse (e.g., oxymetazoline dependence), unilateral nasal inflammatory disease, bilateral inflammatory disease without polyps, or treatment with monoclonal antibodies in the past 12 months, Patients younger than 18 years of age and patients are unfit for general anesthesia.
Where it's running
-
Kafrelsheikh Faculty of Medicine
Egypt, Kafrelsheikh, Canada Recruiting
Study contacts
- Study coordinator: Amr Maher Shady Kafr Elsheikh Hospital University, Doctor
- Email: amrshady00@gmail.com
- Phone: 0201060485163
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Metabolic and Immunologic Biomarkers in Chronic Rhinosinusitis with Nasal Polyps
This study tests whether metabolic and immune markers in nasal tissue and blood differ between people with nasal polyps and those without, to help understand CRSwNP and find potential diagnostic clues.
-
Tezepelumab in real-world CRSwNP: a real-world look at patient outcomes
This study tests tezepelumab in adults with chronic rhinosinusitis with nasal polyps to see how their symptoms and daily life change in routine care over about two years.
-
BBT002 in healthy adults and in people with chronic rhinosinusitis with nasal polyps
This study tests BBT002 versus placebo to see how it acts, how safe it is, and whether it helps people with chronic rhinosinusitis with nasal polyps, with or without asthma.
-
Real-world use of tezepelumab for chronic rhinosinusitis with nasal polyps in Russia
This study will see how tezepelumab works in adults in Russia who have chronic rhinosinusitis with nasal polyps, with or without asthma.
-
Joint pulmonologist and ENT consult for asthma with nasal polyps care
This study tests whether a combined pulmonology and ENT visit helps people with asthma and nasal polyps reduce the need for oral steroids over a year compared to usual separate visits.
-
Real-time detection of eosinophilic nasal polyps using high-sensitivity spectroscopy
This will test a non-invasive light-based device that shines a safe light into the nose to quickly find eosinophilic nasal polyps in adults with chronic rhinosinusitis with nasal polyps.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.